In this phase 2 trial, patients with acute CHF, HTN (SBP >125) and mild-to-moderate renal insufficiency (GFR 30-75) were randomized to placebo or several doses of relaxin (human peptide that increases vasodilation and renal function). The relaxin group had improved dyspnea scores, shorter length of stay, and reduced CV death/CHF readmissions. Serious adverse events were similar between the groups. If confirmed in phase 3 studies, this will likely be a valuable addition to inpatient management of acute CHF (abstract).
Dr. Scheurer is a clinical hospitalist and the Medical Director of Quality and Safety at the Medical University of South Carolina in Charleston, South Carolina, and is Assistant Professor of Medicine. She is a graduate of the University of Tennessee College of Medicine, completed her residency at Duke University, and completed her Masters in Clinical Research at the Medical University of South Carolina. She also serves as the Web Editor and Physician Advisor for the Society of Hospital Medicine.